Reader’s guide · First edition · September 2026 · Revised October 1, 2026
KLOW
A guide to the four-peptide blend vial: GLOW with a gut-inflammation tripeptide added, sold on a mouse colitis model, and a July 2026 committee vote that changed nothing yet
KLOW is GLOW with a fourth ingredient: 50 mg of GHK-Cu, 10 mg of BPC-157, 10 mg of TB-500, and 10 mg of KPV freeze-dried together in one 80 mg vial and sold for skin, healing, and inflammation at once. KPV is the three-amino-acid tail of a natural hormone, alpha-MSH, and its whole record is mouse colitis models and cell studies; no person has received it in a published trial. This guide takes the vial apart: what KPV is and why it was added, what each of the four ingredients has on its own, what the dose arithmetic does to each at the vendor's 3 mL, why a fixed-ratio blend of four is a worse decision than a blend of three, and where each ingredient stands with the FDA after the July 2026 advisory vote.
Who this is for
Written for adults who are using, or being offered, the KLOW blend for skin, hair, recovery, or gut and skin inflammation. It summarizes the published record for each ingredient and the regulatory position as of the edition date. The GLOW guide covers the three-peptide vial in more depth. It is not medical advice.
GLOW is a vendor recipe that packages three best sellers into one purchase. KLOW is the same recipe with a fourth added: KPV, the last three amino acids (lysine, proline, valine) of alpha-melanocyte-stimulating hormone. The hormone's tail was found in the 1990s to carry much of its anti-inflammatory effect in cells, and KPV has since been studied mainly in mouse models of colitis, where it calms gut inflammation when given by mouth or injection. Vendors added it to the blend to sell inflammation alongside skin and healing.
| Ingredient | Amount | Share of the powder | What it is sold for |
|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | Skin firmness, hair, healing |
| BPC-157 | 10 mg | 12.5% | Tendon, gut, and tissue healing |
| TB-500 | 10 mg | 12.5% | Muscle and tendon healing, usually with BPC-157 |
| KPV | 10 mg | 12.5% | Gut and skin inflammation |
By weight it is still a GHK-Cu vial. Five parts in eight of any draw are copper peptide; the ingredient that gives KLOW its name is one part in eight.
- Forms
- Freeze-dried 80 mg blend vials from research vendors, reconstituted by the buyer and injected subcutaneously. KPV is also sold alone as 10 mg vials and as oral capsules.
- Price as sold
- About $95 to $160 a vial, roughly a month of the common protocol; GLOW without the KPV runs $100 to $150
- Status
- No approval, no compounding pathway, no human study of the combination or of KPV. Each ingredient's own status is in section 05.
- Anti-doping
- BPC-157 and TB-500 are prohibited by WADA at all times; a KLOW injection is two banned substances
Four peptides, one syringe, one reaction you cannot trace
A blend of three was already a decision made for the buyer: one ratio, one dose, one schedule. A blend of four makes it worse, because the added ingredient is the least studied of them all and is dosed by whatever the other three happen to need. A buyer who wants KPV for the gut would do better with KPV.
Four ingredients, four evidence records. GHK-Cu, BPC-157, and TB-500 each have a title in this series or an entry in the field guide; the summary here is what matters for the blend. KPV gets more room because this is the only title that covers it.
| Ingredient | Best human evidence | For injection | Grade |
|---|---|---|---|
| GHK-Cu | Small cosmetic studies of creams: firmer skin, fewer fine lines over 12 weeks | None. No human trial of injected GHK-Cu; FDA safety statement never retracted | C topical, D injected |
| BPC-157 | Three small uncontrolled human reports totaling about 30 people; hundreds of rat studies from one laboratory | Those three reports; no controlled trial | C |
| TB-500 | None for the fragment. The full thymosin beta-4 protein has small trials for venous ulcers and eye surface disease, with mixed results and one failed Phase 3 | None | D |
| KPV | None. Mouse colitis models (oral and injected), cell studies of skin and gut cells | None | D |
The combination: no study, no case series, no measurement in anyone. Every claim for KLOW is a claim for one ingredient, borrowed.
The KPV record is worth stating plainly because sellers describe it as the anti-inflammatory peptide. In 2008 two groups showed that KPV given to mice with chemically induced colitis reduced inflammation, one of them tracing the effect to a gut transporter, PepT1, that carries the tripeptide into intestinal cells. Cell studies show it damps the NF-kB inflammatory pathway in gut and skin cells. That is a real mechanism and a real animal result. It has never been followed by a human trial of any kind, by any route, for any condition, in the eighteen years since.
The ingredient the vial is named for is the one with the least evidence
GHK-Cu carries the only human evidence in the vial, and all of it is from creams. BPC-157 has three small uncontrolled reports. TB-500 and KPV have none. The K in KLOW is the weakest link, added last, dosed by convenience.
A rational combination has three properties: each part has evidence on its own, the parts act by different mechanisms so they add rather than overlap, and the combination has been tested together at the ratio sold. Approved combination drugs meet all three. KLOW meets none, and its fourth ingredient makes the second test look better than it is.
| Test | KLOW |
|---|---|
| Each part works alone in humans | One part has cosmetic evidence, by a different route. The other three have nothing controlled |
| The parts act by different mechanisms | Three are sold on the same story: new blood-vessel growth and cell migration into tissue. KPV is sold on a different one, damping inflammation, which is the only thing in the vial that adds rather than overlaps. It is also the only ingredient with no human data at all |
| The combination was tested at this ratio | Never. 50:10:10:10 is a manufacturing convenience |
| Stability of the mixture | Untested. Four peptides with different chemistries, one carrying copper, freeze-dried together and reconstituted for a month of use |
The practical consequence is on the syringe. A dose of blend is a dose of the mixture, so the buyer cannot raise KPV for a gut flare without raising the copper peptide, cannot drop one ingredient that causes a reaction, and cannot tell which of four syntheses' impurities produced a red, swollen injection site.
How it is used, and what each ingredient actually gets9
| Protocol | Instruction | What is known |
|---|---|---|
| Vendor standard | 80 mg vial with 3 mL of water; 10 units (2.67 mg of blend) once daily, subcutaneous, for 4 to 8 weeks | No human study; the dose is the one that makes a vial last a month |
| Low-dose variant | 500 mcg to 1 mg of blend daily | Cuts every ingredient to a fraction of the doses their own sellers recommend |
| KPV alone, for comparison | 200 to 500 mcg daily by injection, or oral capsules | No human study either; the injected dose is a seller's choice |
| Cycling | 4 to 8 weeks on, then a break | Custom; no data on whether breaks matter |
What the next tables are, and are not
They express the vendor protocol for the 80 mg vial as sold, so the arithmetic can be checked, and they show what each ingredient receives at that dose. Nothing here has been tested in a human trial, none of the ingredients may lawfully be compounded, and a research-chemical blend's identity, ratio, and sterility are unverified.
- Vial
- 80 mg blend (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV), as sold; identity, ratio, and quantity unverified
- Water added
- 3 mL bacteriostatic water, the vendors' own instruction and the same as GLOW, so the draw does not change between the two vials; a 3 mL glass vial holds it
- Concentration
- 26.7 mg/mL of blend, which is 16.7 mg/mL GHK-Cu and 3.3 mg/mL each of BPC-157, TB-500, and KPV. One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe; the standard draw is 10 units
- How long a vial lasts
- 3 mL is 30 draws of 10 units: 30 days of daily dosing on paper, 28 or 29 in practice once the liquid lost in each needle is counted. That matches the 4 weeks a reconstituted vial is conventionally kept.
| Weeks | Daily dose | Draw | Units | Used per 4 weeks |
|---|---|---|---|---|
| 1–4 | 2.67 mg of blend | 0.1 mL | 10 | 75 mg (1 vial, with two doses to spare) |
| 5–8 | 2.67 mg of blend, or stop | 0.1 mL | 10 | 75 mg (a second vial) |
| After 8 | Stop and reassess |
A 5-unit draw halves every ingredient and stretches the vial to 60 draws, but not to 60 days: no one has tested a reconstituted four-peptide blend past any date, and the convention for bacteriostatic water is about 4 weeks. At half dose, half the vial is discarded.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
| Ingredient | Per 10-unit dose | Sold alone at | Share |
|---|---|---|---|
| GHK-Cu | 1.67 mg (about 0.23 mg copper) | 1 to 2 mg daily | A full dose |
| BPC-157 | 333 mcg | 250 to 500 mcg daily | A full dose |
| TB-500 | 333 mcg daily (2.3 mg a week) | 2 to 2.5 mg twice weekly, then weekly | Half to a quarter |
| KPV | 333 mcg | 200 to 500 mcg daily | A full dose |
At the vendor's 10-unit dose the blend delivers ordinary seller doses of GHK-Cu, BPC-157, and KPV and a reduced dose of TB-500. That does not make the combination tested. It makes it four untested injections in one. Against GLOW, the only change is the blend figure (2.67 mg against 2.33 mg): the fourth peptide is added on top, not carved out of the other three.
- The vendors' own protocol quietly doubles as a copper protocol: 1.67 mg of GHK-Cu a day is the clinic's GHK-Cu dose, so a KLOW user is running a full injected copper-peptide course whether they wanted one or not.
- The reconstituted vial is blue, from the copper. A KLOW vial that mixes clear is missing its main ingredient.
- KPV's mouse evidence is largely for oral dosing, where the gut transporter that carries it was the point of the study. Injecting it bypasses that route; whether injected KPV reaches the gut lining at a useful dose is unstudied.
- There is no way to taper one ingredient. A buyer who wants to keep KPV and drop the copper peptide has to buy KPV.
No regulator has ever looked at KLOW, because there is nothing to look at: a blend of unapproved substances has no sponsor, no application, and no route to a pharmacy. What FDA has looked at is each ingredient, and in July 2026 its advisory committee voted on three of the four.
| Ingredient | Status | What changed in 2026 |
|---|---|---|
| GHK-Cu (injected) | Unapproved drug; not compoundable; FDA safety statement never retracted | Left Category 2 in April when its nomination was withdrawn; committee review promised by February 2027 |
| BPC-157 | Unapproved; not compoundable | Left Category 2 in April; advisory committee voted 8 to 6 with one abstention in July to recommend listing; rulemaking pending |
| TB-500 | Unapproved; not compoundable; WADA-prohibited | Same path as BPC-157: April removal, 8 to 6 vote in July, rulemaking pending |
| KPV | Unapproved; not compoundable | Nominated for wound healing and inflammatory conditions; 8 to 6 vote in July over FDA staff's objection that it lacks human safety or efficacy data; rulemaking pending |
An advisory vote is a recommendation. Until FDA finishes rulemaking, none of these is on the list, and even then each would be listed alone. Nothing in the process contemplates a 50:10:10:10 blend.
Even a best case leaves the blend outside the law
Suppose FDA lists BPC-157, TB-500, and KPV next year and later lists injectable GHK-Cu too. A pharmacy could then compound each on a prescription. It still could not sell KLOW: a compounded preparation is made to a prescriber's order for a patient, not to a vendor's recipe. The blend vial is a research-chemical product by nature, not by timing.
- FDA's stated concern for injectable GHK-Cu, immune reactions from aggregated peptide and impurities, applies with more force to a vial that also carries the impurities of three other syntheses.
- FDA's reviewers told the committee in July that KPV, like the others, lacks a universally accepted chemical definition, which is what makes a compounded version hard to test for identity. A blend compounds that problem four times.
- Vendors label the blend 'research use only' and sell it with a dosing chart and bacteriostatic water. FDA's August 2026 warning letters to five peptide sellers cited exactly that combination as evidence of intent for human use.
- An athlete who injects KLOW has taken two prohibited substances. Contaminated-supplement defenses do not cover a product whose label lists them.
Reading a blend vial: the arithmetic in five parts9
A single-peptide vial has one concentration. A blend has one for the mixture and one for each ingredient, and the per-ingredient numbers are what matter, because that is what the body receives. Sellers quote the blend figure; buyers should compute the rest.
ingredient per dose = blend dose × (ingredient mg ÷ vial mg)
In KLOW, GHK-Cu is 50 of 80 mg, so a 2.67 mg blend dose carries 1.67 mg of it; BPC-157, TB-500, and KPV are 10 of 80 each, so 0.33 mg apiece. Units come from the blend concentration: 80 mg in 3 mL is 26.7 mg/mL, and 2.67 mg is 0.1 mL, or 10 units.
| Draw | Blend | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|---|
| 2 units (not measurable) | 0.53 mg | 0.33 mg | 67 mcg | 67 mcg | 67 mcg |
| 5 units | 1.33 mg | 0.83 mg | 167 mcg | 167 mcg | 167 mcg |
| 10 units | 2.67 mg | 1.67 mg | 333 mcg | 333 mcg | 333 mcg |
| 20 units | 5.33 mg | 3.33 mg | 667 mcg | 667 mcg | 667 mcg |
30 draws of 10 units per vial. If a seller's instructions use a different water volume, every line changes: at 4 mL the concentration is 20 mg/mL and 10 units is 2 mg of blend. Reconstituted blends have no tested beyond-use date; refrigerate and assume degradation within weeks.
Nothing is known about the safety of the combination because it has never been studied. What is known about each ingredient adds up, and the blend adds a problem of its own: a reaction cannot be attributed.
- Reported
- Injection-site pain, redness, and swelling; flushing; fatigue; light-headedness. Community reports for the blends and for GHK-Cu alone, uncounted.
- Attribution
- With four peptides in one syringe, a rash, a swollen site, or a systemic reaction cannot be traced to its cause, and the only remedy is to stop everything.
- Shared mechanism
- Three ingredients are sold on promoting new blood-vessel growth and cell migration, the programs tumors depend on. None has been studied in anyone with cancer or a cancer history.
- KPV
- A fragment of a hormone that also drives pigmentation; the tripeptide is reported not to act on the pigment receptor, but that is a cell-culture finding. No human safety data by any route.
- Copper
- About 0.23 mg per 10-unit dose, a quarter of the daily dietary allowance; not a plausible overload, but unmeasured by injection. See the GHK-Cu guide.
- Product
- FDA's concern for injected GHK-Cu: aggregation, impurities, immune reactions. A blend carries four syntheses' impurities and an untested mixture chemistry.
- Sterility
- Research-chemical vials are not certified sterile or endotoxin-free for injection, and a blend vial is opened daily for a month.
- Unknown
- Pregnancy, copper disorders, inflammatory bowel disease under treatment, use with other injected peptides, and anything beyond eight weeks.
- Athletes
- Two prohibited substances per injection; a positive test at any time.
- Which of the four ingredients am I actually buying this for? Would that one, alone, at its own dose, do the job?
- If it is the KPV: do I know that no person has ever received KPV in a published study, by any route, for any condition?
- What is the evidence for that ingredient by injection? (For GHK-Cu, TB-500, and KPV, none; for BPC-157, three small uncontrolled reports.)
- What does each ingredient receive per dose at the water volume I am using? Is the TB-500 a fraction of what it is sold at alone?
- If I get a reaction, how will I know which of four peptides caused it?
- Can the seller show a certificate of analysis for this lot with identity, ratio, and sterility, not purity alone?
- Do I have a cancer history, a copper disorder, inflammatory bowel disease under treatment, or am I subject to anti-doping rules?
- What is being measured to decide whether it works, and by when?
What does have evidence for what KLOW is sold for
For skin: daily sunscreen, tretinoin, and copper peptide or vitamin C serums applied to the skin. For tendon and ligament injury: progressive loading under a physical therapist, sleep, protein, and time. For gut inflammation: a gastroenterologist and the approved drugs for inflammatory bowel disease, which have outcome trials in thousands of people. Every one of these has more human evidence than the vial.
Latest
Developments since this edition, newest first. Items here are dated and sourced; they update the guide without re-editing it.
NPR: injected GHK-Cu, the largest ingredient in the vial, has no published human studies
NPR reported that the move from copper-peptide creams to GHK-Cu injections has no published human safety or efficacy data behind it. A Seattle-area nurse practitioner described injection-site infections and patients with raised liver enzymes and copper levels after self-injecting; these are clinic observations, not a published case series.
UCLA review of 565 studies finds almost no human evidence for six popular recovery peptides
Orthopedic researchers reviewed 565 studies of BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, and GHK-Cu for muscle, tendon, and joint use (American Journal of Sports Medicine, 2026). More than two-thirds were animal-only, and the authors found essentially no studies showing a significant clinical benefit for musculoskeletal conditions.
Six peptides recommended; none compoundable until a final rule
The pharmacists' association reports the committee recommended BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax, that the votes are nonbinding, and that pharmacies may not compound any of them until rulemaking is complete. GHK-Cu, the bulk of a GLOW vial, was not reviewed.
Tallies confirmed: BPC-157, KPV, and TB-500 each 8 to 6 with one abstention
A law-firm summary gives the full tallies and notes rulemaking may extend into 2027 or beyond. GHK-Cu is deferred to a meeting before the end of February 2027, so even after any rule the three- and four-peptide blends could not be compounded as sold.
FDA scientists objected to the peptide recommendations
FDA staff told the committee the compounds lack universally accepted chemical definitions, which makes safety and effectiveness hard to evaluate; the committee voted 8 to 6 for BPC-157, KPV, and TB-500 anyway.
Panel narrowly backs BPC-157, KPV, TB-500, and MOTS-c
Coverage framed the day-one votes as a win for the HHS secretary's push on peptides and noted the recommendations do not bind FDA, though the agency rarely overrules its panels.
References
- 1.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- 2.Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- 3.Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- 4.Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- 5.U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (BPC-157, TB-500, KPV, MOTS-c, epitalon, Semax, emideltide). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 6.U.S. Food and Drug Administration. Bulk drug substances nominated for compounding under section 503A (April 2026: withdrawn nominations including GHK-Cu, BPC-157, TB-500, KPV). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- 7.U.S. Food and Drug Administration. Bulk drug substances that may present significant safety risks (injectable GHK-Cu); and warning letters to five peptide vendors, August 24, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- 8.World Anti-Doping Agency. The Prohibited List 2026: S0 (non-approved substances, including BPC-157) and S2 (including TB-500). https://www.wada-ama.org/en/prohibited-list
- 9.Representative KLOW (80 mg) and GLOW (70 mg) blend listings and reconstitution instructions from research-chemical vendors, as sold September 2026. https://thepeptidecatalog.com/articles/klow-blend-buying-guide
- 10.Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.